EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS

被引：21

作者：

HOPEWELL, P

CYNAMON, M

STARKE, J

ISEMAN, M

OBRIEN, R

机构：

[1] SYRACUSE VET ADM MED CTR,DIV INFECT DIS,SYRACUSE,NY

[2] BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030

[3] NATL JEWISH HOSP,DENVER,CO

[4] DIV TB CONTROL,ATLANTA,GA

来源：

CLINICAL INFECTIOUS DISEASES | 1992年 / 15卷

关键词：

D O I：

10.1093/clind/15.Supplement_1.S282

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This guideline addresses the evaluation of new antimycobacterial drugs in the treatment and prevention (secondary prophylaxis) of infection by M. tuberculosis. Patients may be enrolled in clinical trials on the basis of clinical and/or microbiological criteria. A therapeutic regimen will likely include a combination of drugs; a randomized, active-control, comparative clinical trial is recommended. If appropriate samples can be obtained for culture during follow-up without placing the patient at unwarranted risk, the assessment of microbiological outcome is paramount. Prophylaxis will probably require a single drug, and a similar study design is preferred.

引用

页码：S282 / S295

页数：14